-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Symposia: Multiple Myeloma: Pharmacologic Therapies Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Martin F Kaiser, MD1, Andrew Hall2*, Rachel Phillip3*, Amy Holroyd4*, Elsa Ferris4*, Sadie Roberts3*, Laura Clayton2*, Kristian Bowles, MBBS, PhD5, Mamta Garg, MD6*, Anand Lokare7*, Ruth M de Tute, MSc, PhD, FRCPath8*, Mark Drayson9*, Christina Messiou10*, Roger G Owen, MD, MRCP, FRCPath8*, Richard S Houlston4*, Graham Jackson, MD11*, Gordon Cook, PhD, DSc12,13,14*, Guy Pratt15*, Sarah R Brown, PhD3* and Matthew W. Jenner16*

1The Royal Marsden NHS Foundation Trust, London, United Kingdom
2Cancer Research UK Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
3Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
4The Institute of Cancer Research, London, United Kingdom
5Norwich Medical School, University of East Anglia, Norwich, United Kingdom
6University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
7Department of Haematology, Heartlands Hospital, University Hospitals Birmingham, Birmingham, United Kingdom
8HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
9University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom
10The Royal Marsden Hospital, Department of Radiology, London, United Kingdom
11University of Newcastle, Department of Haematology, Newcastle, United Kingdom
12CRUK Clinical Trials Unit, Leeds Institute of Clinical Tial Research, Leeds Myeloma Research Group and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
13Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre, Leeds, United Kingdom
14Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
15University Hospitals Birmingham NHS FT, Birmingham, United Kingdom
16University Hospital Southampton, Southampton, United Kingdom

Shebli Atrash, MD, MS1, Sarah A. Holstein, MD, PhD2, Hira Mian, MD3, Meletios A. Dimopoulos, MD4, Fredrik Schjesvold, MD, PhD5, Rakesh Popat, MBBS, PhD6, Nishi Shah, MBBS, MPH7, Moshe E Gatt, MD8, Christian B. Gocke, MD, PhD9, Laurent Frenzel10*, Cyrille Touzeau, MD, PhD11*, Meral Beksac, MD12, Salomon Manier, MD, PhD13, Hila Magen14*, Patrick M. Travis, MD15*, Omar Nadeem, MD16, Kaveri Suryanarayan17*, Shuli Li17*, Xavier Parot17* and Dan T. Vogl, MD, MS18

1Levine Cancer Institute, Charlotte, NC
2University of Nebraska Medical Center, Omaha, NE
3McMaster University, Hamilton, ON, Canada
4National and Kapodistrian University of Athens, Athens, Greece
5Oslo University Hospital, Oslo, Norway
6University College London Hospital, London, United Kingdom
7Montefiore Medical Center, New York, NY
8Hadassah University Hospital, Jerusalem, Israel
9Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
10Necker Hospital, Paris, France
11Centre Hospitalier Universitaire de Nantes, Nantes, France
12Hematology, Istinye University Ankara Liv Hospital, Ankara, Turkey
13Lille University Hospital, Lille, France
14Sheba Medical Center, Ramat Gan, Israel
15Highlands Oncology Group, P.A., Fayetteville, AR
16Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
17Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
18Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Gang An1*, Lijie Xing, MD2*, Wenming Chen3*, Yan Zhang4*, Wen Gao5, Lu-Gui Qiu, M.D.1, Guojin Wu, PhD6*, Jinying Ning, PhD6*, Min Wei7* and Feng Li, PhD7*

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2Department of Lymphoma and Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji Nan, China
3Department of Hematology, Beijing Chao-Yang Hospital of Capital Medical University, Beijing, China
4Shandong First Medical University (Shandong Academy Of Medical Sciences), Jinan, China
5Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
6KYinno Biotechnology (Beijing) Co., Ltd., Beijing, China
7Beijing Mabworks Biotech Co., Ltd., Beijing, China

Carolina Schinke, MD1, Gareth Morgan, M.D., Ph.D.2*, Luciano J. Costa, MD, PhD3, Natalie Callander, MD4, Don A. Stevens, MD5, Jesus G Berdeja, MD6, Brea Lipe, MD7, Sagar Lonial, MD8*, Marie-Christiane Vekemans9*, Ravi Vij, MD, MBA10, Philippe Moreau, MD, PhD11*, Paula Rodríguez-Otero, MD, PhD12*, Anna Sureda Balari, MD, PhD13, Thomas Renaud, MD14, Jaszianne Tolbert, MD15, Bonnie W Lau15*, Brandi W Hilder, PhD15, Tara J Masterson, MS15*, Michela Campagna, PhD16*, Veronique Vreys17*, Christoph Heuck, MD15*, Colleen Kane, PhD15, Kathleen S Gray18*, Deeksha Vishwamitra15, Indrajeet Singh15*, Joy Gong15*, Xiang Qin15* and Larysa Sanchez, MD19*

1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR
2New York University Langone, New York, NY
3Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Vestavia, AL
4University of Wisconsin, Carbone Cancer Center, Madison, WI
5Norton Cancer Institute, Louisville, KY
6Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN
7University of Rochester Medical Center, Rochester, NY
8Winship Cancer Institute, Atlanta, GA
9Cliniques Universitaires Saint-Luc, Brussels, Belgium
10Washington University School of Medicine, Saint Louis, MO
11University Hospital Hôtel-Dieu, Nantes, France
12Clinica Universidad de Navarra, Madrid, Spain
13Institut Català d'Oncologia – Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
14Janssen Research & Development, Raritan, NJ
15Janssen Research & Development, Spring House, PA
16Janssen Research & Development, Madrid, Spain
17Janssen Research & Development, Beerse, Belgium
18Janssen Research & Development, Bridgewater, NJ
19Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY

Angely Loubert1*, Laurine Bunod1*, Manal M'Hari, MSc1*, Farrah Pompilus2*, Molly Purser, PhD3* and Simon McNamara, PhD4*

1Modus Outcomes, Lyon, France
2GSK, Boston, MA
3GSK, Collegeville, PA
4GSK, Stevenage, Hertfordshire, United Kingdom

Vania Hungria, MD, PhD1, Marek Hus, MD, PhD2*, Pawel Robak, MD, PhD3*, Vera Zherebtsova, MD4*, Ana Carolina de Almeida Ribas, PhD, MSc5*, Marcelo Pitombeira de Lacerda, MD, PhD6*, Kihyun Kim, MD7*, Sebastian Grosicki, MD, PhD8*, Irwindeep Sandhu, MD9*, Christopher Ward, MD, PhD10*, Astrid McKeown, PhD11*, Hena Baig, BS12*, Jie Ma, PhD13, Benjamin Lariviere13*, Benga Kazeem, PhD11*, Lydia Eccersley, MBBS, MRCP, FRCPath, PhD14*, Sumita Roy-Ghanta, MD15*, Joanna Opalinska, MD, PhD16 and Maria Victoria Mateos, MD, PhD17

1Clinica São Germano, São Paulo, Brazil
2Medical University of Lublin, Lublin, Poland
3Medical University of Lodz, Lodz, Poland
4Gorodskaya Klinicheskaya Bol’nitsa Im. S.p. Botkina, Moscow, Russian Federation
5Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis, Brazil
6Universidade da Região de Joinville (Univille), Joinville, Santa Catarina, Brazil
7Sungkyunkwan University, Samsung Medical Center, Seoul, Korea, Republic of (South)
8Medical University of Silesia, Katowice, Poland
9University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
10Royal North Shore Hospital, Sydney, NSW, Australia
11GSK, Stevenage, United Kingdom
12GSK, Mississauga, Ontario, CAN
13GSK, Waltham, MA
14GSK, London, United Kingdom
15GSK, Upper Providence, PA
16GSK, Philadelphia, PA
17Hospital Universitario de Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain

Omar Nadeem, MD1, Sophie Magidson, BS2*, Robert A. Redd, MS3*, Jacob P. Laubach2*, Clifton C. Mo, MD2, Elizabeth K. O'Donnell, MD2, Adam S. Sperling, MD, PhD4, Monique A. Hartley-Brown, MD2, Shonali Midha, MD5*, Yuxin Liu, MD2, Frances Arters, PA-C6*, Marjorie Marto2*, Christine Davie2*, Caroline Ricciardi2*, Dechen Choden2*, Ashlee Strutevant2*, Jillian Alberti2*, Amy Goguen2*, Michael Constantine, MD7*, Pedro Sanz-Altamira, MD, PhD6*, Lorenzo Trippa, PhD3*, Nikhil C. Munshi, MD2, Kenneth C. Anderson, MD2, Paul G. Richardson2 and Irene Ghobrial, MD2

1Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
4Division of Hematology, Brigham and Women's Hospital, Boston, MA
5Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
6Dana-Farber Cancer Institute, Boston
7Dana-Farber Cancer Institute, Milford, MA

Evangelos Terpos, MD, PhD1, Efstathios Kastritis, MD1*, Sosana Delimpasi, MD2*, Maria Kotsopoulou, MD3*, Konstantina Papathanasiou, MD4*, Vasiliki Labropoulou, MD5*, Eirini Katodrytou6*, Ioannis Ntanasis-Stathopoulos, MD, PhD, MSc1*, Panagiotis Malandrakis, MD1*, Despina Fotiou, MD1*, Magdalini Migkou, MD1*, Foteini Theodorakakou, MD1*, Vasiliki Spiliopoulou, MD1*, Nikolaos Kanellias1*, Evangelos Eleutherakis-Papaiakovou, MD1*, Giorgos Psarros, MSc7*, Maria Gavriatopoulou1* and Meletios Dimopoulos, MD1

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece
3Department of Hematology, Metaxa Cancer Hospital, Piraeus, Greece
4Department of Hematology, Faculty of Medicine, University of Ioannina, Ioannina, Greece
5Hematology Division, Department of Internal Medicine, University of Patras, Medical School, Patras, Greece
6Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece
7Health Data Specialists, Dublin, Ireland

Sridevi Rajeeve, MD1, Andriy Derkach, PhD2*, Sean M. Devlin, PhD2*, Jeannen Santos3*, Anna Przemielewska3*, Tara Sood4*, Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA4, Hamza Sloan Hashmi, MD5*, Carlyn Rose Tan, MD6, Neha Korde, MD4, Malin Hultcrantz, MD4, Parastoo B Dahi, MD7*, Alexander M. Lesokhin, MD8, Michael Scordo, MD9, David J. Chung, MD, PhD10, Heather J. Landau, MD10, Gunjan L. Shah, MD7, Ola Landgren11, Sergio A. Giralt, MD12, Sham Mailankody, MD, MBBS4, Saad Z. Usmani, MD4 and Urvi A. Shah, MD4

1Myeloma & Cellular Therapy Services/Dept of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
3Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
4Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5Myeloma Service, Department of Medicine, Memorial Sloan Kettering, New York, NY
6Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Ardmore, PA
7Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
8Myeloma & Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
9Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY
10Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
11Sylvester Comprehensive Cancer Center, Miami, FL
12Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Zachary J. Walker, BS, MS*, Deng Wang*, Sarah E. Parzych, BA*, Lauren T. Reiman, BSc*, Jacob Joram*, Meghan Straubel*, Alfonso Roque*, Kaylynn Imsande*, Katie Zhou*, Peter A. Forsberg, MD and Daniel W. Sherbenou, MD, PhD

Division of Hematology, University of Colorado Anschutz Medical Campus, Aurora, CO

Binod Dhakal, MBBS1, Hang Quach, MD, FRACP, FRCPA, MBBS2, Phoebe Joy Ho, MBBS3, Andrew Spencer, MBBS, DM (Lond), FRACP, FRCPA4*, Mark A. Schroeder, MD5, Peter T. Tan, MBBS6, Tara Cochrane, MBBS, FRCPA, FRACP7, Hanlon Sia, MBBS FRACP FRCPA8*, Jeffrey A. Zonder, MD 9, Camille Martinet10*, Dominique Duchesne11*, Andrew Garton, PhD11*, Vinu Menon12*, Beata Holkova, MD13, Cyril Konto, MD12, Lida Pacaud, MD14* and Dickran Kazandjian, MD15

1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
2St. Vincent's Hospital Melbourne, East Melbourne, Australia
3Royal Prince Alfred Hospital, Camperdown, NSW, Australia
4Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
5Division of Oncology, Washington University School of Medicine, St. Louis, MO
6One Clinical Research, Nedlands, Australia
7Gold Coast University Hospital and Griffith University, Gold Coast, QLD, Australia
8Pindara Private Hospital, Gold Coast, Australia
9Karmanos Cancer Institute, Detroit, MI
10Medqualis, Montreal, Canada
11Ichnos Sciences Inc., New York
12Ichnos Sciences, New York, NY
13Ichnos Sciences Inc, New York
14Ichnos Sciences Inc., New York, NY
15Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Natalie Callander, MD1, Gayathri Ravi, MD2, Rebecca W. Silbermann3, Zhubin J. Gahvari, MD, MS4, Eva Medvedova, MD5*, Bhagirathbhai R. Dholaria, MBBS6, Naresh Bumma, MD7, Doris K. Hansen, MD8, Everette M Colquette9*, Pamela Hardwick9* and Luciano J. Costa, MD, PhD10

1University of Wisconsin, Carbone Cancer Center, Madison, WI
2Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
3Oregon Health and Science University, Portland, OR
4Carbone Cancer Center, University of Wisconsin-Madison, Madison
5Knight Cancer Institute, Oregon Health & Science University, Portland, OR
6Vanderbilt University Medical Center, Nashville, TN
7The Ohio State University Comprehensive Cancer Center, COLUMBUS, OH
8Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
9O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
10Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Vestavia, AL

Binod Dhakal, MBBS1, Andrew J. Yee, MD2, Paul G. Richardson3, Sikander Ailawadhi, MD4, Saurabh Chhabra, MD5, Eli Muchtar, MD6, Jesús G. Berdeja, MD7, Shambavi Richard, MD8, Jeffrey V Matous, MD9, Urvi A. Shah, MD10, Mark A. Schroeder, MD11, Amro Ali, PharmD12*, Leah Leahy, BS12*, Riadh Lobbardi, PhD12*, Rong Chu, PhD12*, Eunju Hurh, PhD12*, Anthony S. Fiorino, MD, PhD12* and Sagar Lonial, MD13*

1Medical College of Wisconsin, Milwaukee, WI
2Massachusetts General Hospital Cancer Center, Boston, MA
3Dana-Farber Cancer Institute, Boston, MA
4Division of Hematology-Oncology, Mayo Clinic-Florida, Jacksonville, FL
5Division of Hematology, Mayo Clinic, Phoenix, AZ
6Division of Hematology, Mayo Clinic, Rochester, MN
7Tennessee Oncology, Nashville, TN
8Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
9Sarah Cannon Research Institute, Colorado Blood Cancer Institute, Denver, CO
10Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
11Division of Oncology, Washington University School of Medicine, St. Louis, MO
12C4 Therapeutics, Watertown, MA
13Winship Cancer Institute, Emory University, Atlanta, GA

Isha Mol1*, Yannan Hu, PhD1*, Thomas W. LeBlanc, MD, MA, MS2, Joseph C. Cappelleri, PhD3*, Haitao Chu, PhD, MD4*, Guido Nador5*, Didem Aydin, MD, PhD6*, Isabel Perez-Cruz4* and Patrick Hlavacek4*

1Cytel, Rotterdam, Netherlands
2Duke Cancer Institute, Hillsborough, NC
3Pfizer Inc, Groton, CT
4Pfizer Inc, New York, NY
5Pfizer Ltd, Surrey, United Kingdom
6Pfizer Inc, Istanbul, Turkey

Murali Janakiram, MD1, Carlyn Rose Tan, MD2, Rakesh Popat, MBBS, PhD3, Joaquín Martínez Lopez4*, Efstathios Kastritis, MD5*, Chris Lau6*, Wee-Joo Chng, FRCP, FRCPath, PhD7, Prashant Kapoor, MD8, Hira Mian, MD9, Susan Bal, MD10*, Ajay K. Nooka, MD, MPH11, Andre De Menezes Silva Corraes, MD12*, Magdalena Corona13*, Arnab Chowdhury, PhD1*, Yi Lin, MD, PhD12, Thomas G. Martin, MD14 and Amrita Y Krishnan, MD, FACP15

1Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
2Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Ardmore, PA
3UCL Cancer Institute, University College London, London, United Kingdom
4Department of Hematology, Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid, Spain
5Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Voula,Athens, AL, Greece
6NIHR/University College London Hospital Clinical Research Facility, NHS Foundation Trust, London, United Kingdom
7National University Cancer Institute of Singapore, Singapore, Singapore
8Mayo Clinic, Rochester, MN
9McMaster University, Hamilton, ON, Canada
10University of Alabama at Birmingham, Birmingham, AL
11Winship Cancer Institute of Emory University, Atlanta
12Division of Hematology, Mayo Clinic, Rochester, MN
13University of Complutense, Hospital 12 de Octubre, Madrid, Spain
14Department of Hematology, University of California at San Francisco, San Francisco, CA
15City of Hope Comprehensive Cancer Center, Duarte, CA

Mansi R. Shah, MD1, Joshua Richter, MD2, Hans C. Lee, MD3, Attaya Suvannasankha4*, James E. Hoffman5, Suzanne Lentzsch, MD, PhD6, Sundar Jagannath2, Jeffrey A. Zonder, MD 7, Rachid Baz, MD8, Swathi Namburi9, Ka Lung Wu10, Madhav V. Dhodapkar, MD PhD11, Joseph J. Maly12*, Rebecca Silbermann13, Chang-Ki Min14*, Matthew Pianko15, Marie-Christiane Vekemans16*, Markus Munder17*, Ja Min Byun, MD, PhD18, Joaquín Martínez-Lopez19*, Michelle DeVeaux20*, Dhruti Chokshi20*, Megan Seraphin20*, Anita Boyapati20*, Anasuya Hazra20*, Glenn S. Kroog20*, Kate Knorr20* and Naresh Bumma, MD21

1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2Icahn School of Medicine at Mount Sinai, New York, NY
3The University of Texas MD Anderson Cancer Center, Houston, TX
4Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN
5University of Miami Health System, Miami, FL
6Columbia University Medical Center, New York, NY
7Karmanos Cancer Institute, Detroit, MI
8Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
9Swedish Cancer Institute, Seattle, WA
10Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
11Emory University, Atlanta, GA
12Norton Cancer Institute, Louisville, KY
13Knight Cancer Institute, Oregon Health & Science University, Portland, OR
14Department of Hematology, Seoul St. Mary's Hospital,The Catholic University of Korea, Seoul, Korea, Republic of (South)
15Rogel Cancer Center, University of Michigan, Ann Arbor, MI
16Department of Internal Medicine, Université Catholique de Louvain (UCLouvain), Brussels, Belgium
17Third Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
19Hospital Universitario 12 de octubre, Universidad Complutense, CNIO, Madrid, Spain
20Regeneron Pharmaceuticals, Inc., Tarrytown, NY
21The Ohio State University Comprehensive Cancer Center, Columbus, OH

Pierre Bories, MD1*, Cristina Gasparetto, MD2*, David Dingli, MD, PhD3, Sagar Lonial, MD4*, Saad Z. Usmani, MD5, Jesus G Berdeja, MD6, Alfred Chung, MD7, Aimaz Afrough, MD8, Laura Rosiñol, MD, PhD9*, Andrew J. Yee, MD10*, Suzanne Trudel, MD, MSc11,12, David S. Siegel, MD, PhD13, Paula Rodríguez-Otero, MD, PhD14*, Soo Bang, MHSA15*, Terry Connolly, PhD15*, Chad A. Lewis, PhD15*, Erin Flynt, PhD15*, Julie Vazquez, RN, MSN15*, Sanjana U. Miskin, MSc15*, Benjamin Winograd, MD, PhD15*, Maria-Victoria Mateos, MD, PhD16, Cyrille Touzeau, MD, PhD17,18* and Vivek Roy, MD19

1Department of Hematology, Toulouse University Institute of Cancer, Toulouse, France
2Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
3Division of Hematology, Mayo Clinic, Rochester, MN
4Winship Cancer Institute, Emory University, Atlanta, GA
5Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
6Tennessee Oncology, Nashville
7Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
8Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Coppell, TX
9Hematology, IDIBAPS, Hospital Clinic, Barcelona, ESP
10Massachusetts General Hospital, Boston, MA
11Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada
12Princess Margaret Cancer Centre, Toronto, ON, Canada
13Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
14Clínica Universidad de Navarra, Pamplona, Spain
15K36 Therapeutics, Cambridge, MA
16Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBASL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Salamanca, Spain
17Centre Hospitalier Universitaire de Nantes, Nantes, France
18University Hospital Nantes, Nantes, France
19Division of Hematology-Oncology, Mayo Clinic-Florida, Jacksonville, FL

Charlotte L.B.M. Korst1,2*, Wouter Plattel, MD, PhD3*, Elizabeth de Kort4*, Alexandra Croockewit, MD, PhD4*, Mark-David Levin5, Matthijs Westerman, MD6*, Okke De Weerdt7*, Inger S. Nijhof, MD, PhD7*, Jurgen Wegman1*, Nina Smit1*, Christie P.M. Verkleij, MD1,2*, Tuna Mutis, MD PhD1,2*, Marjolein van der Klift, MD, PhD8*, Laurens Franssen, MD PhD9*, Kaz Groen, MD1,2*, Ellen van der Spek, MD PhD10*, Wilfried Roeloffzen3*, Sonja Zweegman, MD, PhD1,2 and Niels W.C.J. van de Donk, MD, PhD1,2*

1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
2Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands
3Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
4Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands
5Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands
6Department of Internal Medicine, Northwest Clinics, Alkmaar, Netherlands
7Department of Hematology, St Antonius Hospital, Nieuwegein, Netherlands
8Department of Internal Medicine, Amphia Hospital, Breda, Netherlands
9Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands
10Department of Internal Medicine, Rijnstate hospital, Arnhem, Netherlands

Bo Qin, PhD1*, Alexander B Jackman1*, Yao-Cheng Li, PhD1*, Jianying Wang1*, Huang Qiu, PhD1*, Nathan Onpaeng1*, Steven Wilkens, PhD1*, Virginia Grant1*, Robyn L Stanfield, PhD2*, Ian Wilson, PhD2*, Imani Rogers1*, Richard Labaudiniere, PhD1*, Jeffery W Kelly, PhD3*, H Michael Petrassi, PhD1* and Xin Jiang, PhD1*

1Protego Biopharma, San Diego, CA
2Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA
3Department of Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA

Adam D. Cohen, MD1, Sandra Susanibar-Adaniya, MD2, Oksana De Mesa, BSN, RN2*, Alfred L. Garfall, MD2, Dan T. Vogl, MD, MS2, Adam Waxman, MD2*, Shivani Kapur, MD2, E Paul Wileyto3*, Anjana Nair2*, Zainul S. Hasanali, MD, PhD4, Lauren Karpf5* and Edward A. Stadtmauer, MD2

1Abramson Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
3Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadephia, PA
4Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
5Office of Clinical Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Laura Rosiñol Dachs, MD, PhD1*, Albert Oriol, MD, PhD2*, María-Jesús Blanchard, MD, PhD3*, Javier de la Rubia4*, Rafael Ríos, MD, PhD5*, Joan Bargay6*, Miguel Teodoro Hernández Garcia, MD, PhD7*, Valentín Cabanas Perianes8*, Ana López de la Guía9*, Estrella Carrillo-Cruz, MD10*, Anna Sureda Balari, MD, PhD11, Joaquin Martínez-López12*, Jose Maria Arguiñano, MD13*, Esther González García, MD, PhD14*, Luis Felipe Casado15*, Josep Maria Marti Tutusaus16*, Cristina Encinas17*, Felipe De Arriba, MD, PhD18*, Luis Palomera, MD, PhD19*, Antonia Sampol Mayol, MD20*, Yolanda González-Montes, MD, PhD21*, Jordi López-Pardo22*, Maialen Sirvent, PhD23*, Maria Belen Inigo Rodriguez24*, Bruno Paiva, PhD25*, Noemi Puig, PhD26, Maria Teresa Cedena Romero, MD, PhD27*, Norma C. Gutierrez28*, Javier De la Cruz, MD29*, Maria-Victoria Mateos, MD, PhD30, Jesús F. San-Miguel, MD, PhD31, Juan-Jose Lahuerta Palacios, MD, PhD32* and Joan Bladé, MD, PhD33*

1Hematology, IDIBAPS, Hospital Clinic, Barcelona, ESP
2Hematology, Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
3Hematology, Hospital Universitario Ramón y Cajal, Madrid, Spain
4Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
5Hospital Universitario Virgen De Las Nieves, Granada, ESP
6Hematology Department, Hospital Universitario Son Llàtzer. IdIsBa., Palma de Mallorca, Spain
7Hospital Universitario de Canarias, La Laguna, ESP
8Hospital Universitario Virgen de la Arrixaca., Murcia, Spain
9Hospital Universitario La Paz, Madrid, Spain
10Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain
11Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain
12Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, Madrid, Spain
13Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
14Hospital de Cabueñes, Gijón, Spain
15Hematology, Hospital General Universitario de Toledo, Toledo, Spain
16Hospital Universitari Mútua de Terrassa, Terrassa, Spain
17Hospital General Universitario Gregorio MarañóN, Madrid, Spain
18Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
19Hospital Clinico Universitario Lozano Blesa, Instituto Investigacion Sanitaria Aragon, Zaragoza, Spain
20Hematology Department., Hospital Universitario Son Espases, IdISBa., Palma, Spain
21Hematology, Institut d'Oncologia Dr. Josep Trueta, Girona, Spain
22Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
23Hospital de Donostia, San Sebastián, Spain
24HOSPITAL CLINICO SAN CARLOS, MADRID, Spain
25Department of Hematology, Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Pamplona, Spain
26Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain
27Instituto de Investigación IMAS12, Madrid, Spain
28Hospital Universitario De Salamanca, IBSAL, Salamanca, Spain
29Hospital Universitario 12 De Octubre, Instituto De Investigación Sanitaria,, Madrid, Spain
30University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Salamanca, Spain
31Clínica Universitaria de Navarra, Pamplona, Spain
32Hematology, Hospital Universitario 12 de Octubre, Imas12, CIBERONC, Madrid, Spain
33Hospital Clinic, IDIBAPS, Barcelona, Spain

Graham Jackson, MD1*, Charlotte Pawlyn, PhD2,3, Faith E Davies, MD4, Martin F Kaiser, MD2,3, Ruth M de Tute, MSc, PhD, FRCPath5*, Heather McIntyre6*, Jeanine Richards6*, Sharon Jackson6*, Elizabeth Hodson6*, Anna Hockaday6*, Catherine Olivier6*, John R Jones7,8,9*, Matthew W. Jenner10*, Gordon Cook, PhD, DSc6*, Walter Martin Gregory, PhD6*, Mark Drayson11*, Roger G Owen, MD, MRCP, FRCPath5*, David A. Cairns, PhD12* and Gareth Morgan, M.D., Ph.D.4*

1University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
2The Institute of Cancer Research, London, United Kingdom
3The Royal Marsden NHS Foundation Trust, London, United Kingdom
4Perlmutter Cancer Center, Multiple Myeloma Research Program, NYU Langone Health, New York, NY
5HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
6Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
7Kings College Hospital, London, United Kingdom
8Brighton and Sussex Medical School, Brighton, United Kingdom
9East Sussex NHS Trust, Eastbourne, United Kingdom
10University Hospital Southampton, Southampton, United Kingdom
11University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom
12Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

Donna E Reece, MD1, Giovanni Piza Rodriguez, MD2*, Mariela A Pantoja, PhD, MSc3*, Eshetu G Atenafu, MSc, PStat4*, Darrell White, MD, MSc5, Irwindeep Sandhu, MD6, Julie Stakiw, MD7, Michael Sebag, MD, PhD8, Terrance Comeau, MD9, Kevin Song, MD10, Jean Roy, MD11, Martha L Louzada, MD, MSc12, Arleigh McCurdy, MD13, Vishal Kukreti, MD, MSc14, Suzanne Trudel, MD15*, Anca Prica, MD2, Rodger E Tiedemann, MBChB, PhD16 and Christine I Chen, MHPE, MD17

1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre- University Health Network, Toronto, ON, Canada
2Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
3Princess Margaret Cancer Centre, Toronto, ON, CAN
4Princess Margaret Cancer Centre / University Health Network, Toronto, ON, Canada
5Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
6Cross Cancer Institute, Edmonton, AB, Canada
7Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK, Canada
8McGill University, Montréal, QC, Canada
9Saint John Regional Hospital, Saint John, NB, Canada
10BC Cancer Agency, Vancouver General Hospital, Vancouver, BC, Canada
11Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
12London Health Sciences Centre, London, ON, Canada
13The Ottawa Hospital, Ottawa, ON, Canada
14Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
15Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Canada
16Princess Margaret Cancer Centre, Toronto, ON, Canada
17Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada

Gang An1*, Zhongxia Huang2*, Aibin Liang3*, Baijun Fang4*, Hongmei Jing, MD5 and Lu-Gui Qiu, MD1

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology&Blood Diseases Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Tianjin, China
2Multiple Myeloma Medical Center of Beijing, Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
3Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China
4Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China

Terri L. Parker, MD1, Adam Rosenthal, MS2*, Vaishali Sanchorawala3, Heather J. Landau, MD4, Erica L. Campagnaro, MD5*, Prashant Kapoor, MD6, Natalia Neparidze, MD1, Saulius Girnius, MD7, Patrick Hagen, MD, MPH8*, Emma C. Scott, MD9*, Antje Hoering, PhD10, Brian G.M. Durie11 and Robert Z. Orlowski, MD, PhD12

1Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT
2SWOG Statistical and Data Management Center, Seattle, WA
3Section of Hematology and Medical Oncology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA
4Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
6Mayo Clinic, Rochester, MN
7Trihealth Cancer Institute, Cincinnati, OH
8Division of Hematology and Oncology, Loyola University Health System, Maywood, IL
9Oregon Health and Science University, Portland, OR
10Cancer Research And Biostatistics, Seattle, WA
11Cedars-Sinai Medical Center, Los Angeles, CA
12Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

J Christine Ye, MD, MSc1, Philip Boonstra, PhD2*, Erica L. Campagnaro, MD3*, Matthew Pianko4, Andrew Kin, MD5, Larry D Anderson Jr., MD, PhD6, Brea Lipe, MD7, Moshe Talpaz, MD8 and Jeffrey A. Zonder, MD 9

1Department of Lymphoma & Myeloma, UT MD Anderson Cancer Center, Houston, TX
2University of Michigan, Ann Arbor, MI
3Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
4Rogel Cancer Center, University of Michigan, Ann Arbor, MI
5Karmanos Cancer Institute/Wayne State University, Detroit, MI
6Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
7University of Rochester Medical Center, Rochester, NY
8University of Michigan Cancer Center, Ann Arbor, MI
9Karmanos Cancer Institute, Detroit, MI

Evangelos Terpos, MD, PhD1, Maria Gavriatopoulou1*, Ioannis Ntanasis-Stathopoulos, MD, PhD, MSc1*, Panagiotis Malandrakis, MD1*, Despina Fotiou, MD1*, Magdalini Migkou, MD1*, Foteini Theodorakakou, MD1*, Vasiliki Spiliopoulou, MD1*, Rodanthi Syrigou, MD1*, Evangelos Eleutherakis-Papaiakovou, MD1*, Giorgos Psarros, MSc2*, Efstathios Kastritis, MD1* and Meletios Dimopoulos, MD1

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2Health Data Specialists, Dublin, Ireland

Robert Z. Orlowski, MD, PhD1, Shambavi Richard, MD2, Jonathan L. Kaufman, MD3, Sebastian Grosicki, MD, PhD4*, Istvan Takacs5*, Andras Strassz, MD, MBA6, Andreas Martin Pahl, PhD7, Michael Kulke8*, Thorsten Michael, MBA6,9*, Anette Last10*, Hajnalka Szaboki6*, Frank Richard, MD, MBA6*, Oliver Schönborn-Kellenberger, MSc11* and Marc S. Raab12,13*

1Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
3Winship Cancer Institute of Emory University, Atlanta, GA
4Medical University of Silesia, Katowice, Poland
5Ist Department of Medicine, Semmelweis University, Budapest, Hungary
6Heidelberg Pharma AG, Ladenburg, Germany
7Heidelberg Pharma, Ladenburg, Germany
8Heidelberg Pharma Research Gmbh, Ladenburg, Germany
9Heidelberg Pharma AG, Frankfurt am Main, HE, Germany
10Gregor-Mendel-Straße 22, Heidelberg Pharma AG, Ladenbuerg, Germany
11Cogitars GmbH, Heidelberg, Germany
12Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
13Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany

*signifies non-member of ASH